No abstract

No abstract

A growing body of research supports the use of mindfulness-based interventions (MBIs) in incarcerated populations; however, treatment effectiveness remains unclear. This meta-analysis of 22 studies ( N = 2,265, 75% male) quantified the effectiveness of MBIs in incarcerated populations on key psychological outcomes and criminogenic needs. Results from pre–post studies indicated MBIs had a small to moderate effect on all outcomes, but this was not supported by controlled studies. Studies with older participants, more females, and longer treatment length demonstrated slightly greater effects. Results from pre–post analyses demonstrated significant reductions in psychological outcomes (depression, anxiety, and stress) and criminogenic needs (impulsivity, self-dysregulation, anger, substance use behavior, and attitude). However, only depression and anxiety were significantly reduced in controlled studies. Although findings offer preliminary support of the efficacy of MBIs in targeting psychological health in incarcerated populations, further controlled studies are required to examine criminogenic outcomes and recidivism rates after treatment.

No abstract

Prevalence of psychiatric disorders continues to rise globally, yet remission rates and patient outcome remain less than ideal. As a result, novel treatment approaches for these disorders are necessary to decrease societal economic burden, as well as increase individual functioning. The recent discovery of the endocannabinoid system has provided an outlet for further research into its role in psychiatric disorders, because efficacy of targeted treatments have been demonstrated in medical illnesses, including cancers, neuropathic pain, and multiple sclerosis. The present review will investigate the role of the endocannabinoid system in psychiatric disorders, specifically schizophrenia, depressive, anxiety, and posttraumatic stress disorders, as well as attention-deficit hyperactivity disorder. Controversy remains in prescribing medicinal cannabinoid treatments due to the fear of adverse effects. However, one must consider all potential limitations when determining the safety and tolerability of cannabinoid products, specifically cannabinoid content (ie, Δ-tetrahydrocannabinol vs cannabidiol) as well as study design. The potential efficacy of cannabinoid treatments in the psychiatric population is an emerging topic of interest that provides potential value going forward in medicine.